Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pfizer Fined Nearly £90 Million for Epilepsy Drug Price Hike in UK

XTALKS VITALS NEWS

The CMA claimed that the drugmaker was charging “excessive and unfair prices” for the epilepsy medication.

Share this!

December 8, 2016 | by Sarah Hand, M.Sc.

Yesterday, pharmaceutical company Pfizer, and their UK distributer, Flynn Pharma, were fined £89.4 million by British regulators in response to the increasing cost of an epilepsy drug. The companies were accused of raising the price of the medication by almost 2,600 percent.

According to the Competition and Markets Authority (CMA), 48,000 people in the UK use the drug. The CMA claimed that the drugmaker was charging “excessive and unfair prices” for the epilepsy medication.

“This is the highest fine the CMA has imposed and it sends out a clear message to the sector that we are determined to crack down on such behavior and to protect customers, including the NHS, and taxpayers from being exploited,” said Philip Marsden, chairman of the case decision group for the CMA investigation. Pfizer absorbed the bulk of the fine at £84.2 million, while Flynn Pharma was charged the remaining £5.2 million.

The companies reportedly stopped selling the drug under its branded name, Epanutin, in order to raise the price of the phenytoin sodium capsules. In 2002, England’s National Health Service (NHS) spent £2 million on the epilepsy drug; after the price increase in 2013, this bill was increased to £50 million.



“The companies deliberately exploited the opportunity offered by de-branding to hike up the price for a drug which is relied upon by many thousands of patients,” said Marsden. Both Pfizer and Flynn Pharma are opposed to the ruling – with plans to appeal – saying that the company was losing money on sales of Epanutin.

“In this transaction, and in all of our business operations, we approached this divestment with integrity, and believe it fully complies with established competition law,” said a spokesperson from Pfizer. “The ruling highlights real policy and legal issues concerning the respective roles of both the Department of Health and the CMA, in regulating the price of pharmaceutical products in the U.K. Pfizer will seek clarity on these issues as part of the appeal process.”

The company maintains that the revised cost of Epanutin is 25 to 40 percent less compared to an equivalent epilepsy drug. Drug pricing has been a hot button issue in both the UK and the US for the past few years, with pharmaceutical companies facing increased scrutiny regarding their pricing policies.


Keywords: Epilepsy, Drug Pricing, NHS


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.